Evidence map›Paper›PMID 36789164›Full record

ArticleBio-protocol2023

Rapid Multiplexed Flow Cytometric Validation of CRISPRi sgRNAs in Tissue Culture.

John S Chorba, Vivian Q Xia, Geoffrey A Smith, Arun Padmanabhan

Abstract read
In one paragraph

Article in Bio-protocol, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

John S ChorbaDivision of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco CA, USA.
Vivian Q XiaDivision of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco CA, USA.
Geoffrey A SmithDivision of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco CA, USA.
Arun PadmanabhanDivision of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco CA, USA.

Funding

CSDE1 as a Post Transcriptional Regulator of the LDLR - Diversity SupplementR01HL159457 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHORBA, JOHN S · 2021 to 2024
$2.6M
Chemical Biology to Modulate PCSK9 and Treat AtherosclerosisR01HL146404 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHORBA, JOHN S · 2021 to 2024
$1.6M
Probing the multiple roles of the PCSK9 active site using chemical biologyK08HL124068 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHORBA, JOHN S · 2015 to 2019
$878k
Padmanabhan K08 Admin SupplementK08HL157700 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PADMANABHAN, ARUN · 2021 to 2025
$830k
Mediators of PCSK9 Secretion as Targets Against AtherosclerosisR03HL145259 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHORBA, JOHN S · 2018 to 2019
$160k
NHLBI NIH HHS K08 HL124068NHLBI NIH HHS K08 HL157700NHLBI NIH HHS R01 HL146404NHLBI NIH HHS R01 HL159457NHLBI NIH HHS R03 HL145259
6 · The paper itself

Abstract

Genome-wide CRISPR-based screening is a powerful tool in forward genetics, enabling biologic discovery by linking a desired phenotype to a specific genetic perturbation. However, hits from a genome-wide screen require individual validation to reproduce and accurately quantify their effects outside of a pooled experiment. Here, we describe a step-by-step protocol to rapidly assess the effects of individual sgRNAs from CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) systems. All steps, including cloning, lentivirus generation, cell transduction, and phenotypic readout, can be performed entirely in 96-well plates. The system is highly flexible in both cell type and selection system, requiring only that the phenotype(s) of interest be read out via flow cytometry. We expect that this protocol will provide researchers with a rapid way to sift through potential screening hits, and prioritize them for deeper analysis in more complex in vitro or even in vivo systems. Graphical abstract.

Indexed as

CRISPRiFlow cytometryForward geneticsHit validation

Identifiers

PMID36789164
PMCPMC9901452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.